194 related articles for article (PubMed ID: 11291041)
41. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli.
Joshi BH; Puri RK
Protein Expr Purif; 2005 Feb; 39(2):189-98. PubMed ID: 15642470
[TBL] [Abstract][Full Text] [Related]
42. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.
Mintz A; Gibo DM; Madhankumar AB; Debinski W
J Neurooncol; 2003; 64(1-2):117-23. PubMed ID: 12952292
[TBL] [Abstract][Full Text] [Related]
43. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
[TBL] [Abstract][Full Text] [Related]
44. hIL-13-PE38QQR. NeoPharm.
Barth S
Curr Opin Investig Drugs; 2001 Sep; 2(9):1309-13. PubMed ID: 11717820
[TBL] [Abstract][Full Text] [Related]
45. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts.
Kawakami M; Kawakami K; Puri RK
Mol Cancer Ther; 2002 Oct; 1(12):999-1007. PubMed ID: 12481422
[TBL] [Abstract][Full Text] [Related]
46. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.
Leland P; Taguchi J; Husain SR; Kreitman RJ; Pastan I; Puri RK
Mol Med; 2000 Mar; 6(3):165-78. PubMed ID: 10965493
[TBL] [Abstract][Full Text] [Related]
47. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells.
Kunwar S; Pai LH; Pastan I
J Neurosurg; 1993 Oct; 79(4):569-76. PubMed ID: 7692018
[TBL] [Abstract][Full Text] [Related]
48. Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture.
Liu TF; Cohen KA; Willingham MC; Tatter SB; Puri RK; Frankel AE
J Neurooncol; 2003 Oct; 65(1):77-85. PubMed ID: 14649887
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
50. Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals.
Engebraaten O; Hjortland GO; Juell S; Hirschberg H; Fodstad O
Int J Cancer; 2002 Feb; 97(6):846-52. PubMed ID: 11857366
[TBL] [Abstract][Full Text] [Related]
51. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
Shimamura T; Husain SR; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016
[TBL] [Abstract][Full Text] [Related]
52. Identification, characterization, and targeting of IL-4 receptor by IL-4-Pseudomonas exotoxin in mouse models of anaplastic thyroid cancer.
Joshi BH; Suzuki A; Fujisawa T; Leland P; Varrichio F; Lababidi S; Lloyd R; Kasperbauer J; Puri RK
Discov Med; 2015 Nov; 20(111):273-84. PubMed ID: 26645899
[TBL] [Abstract][Full Text] [Related]
53. Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy.
Joshi BH; Leland P; Calvo A; Green JE; Puri RK
Cancer Res; 2008 Nov; 68(22):9311-7. PubMed ID: 19010904
[TBL] [Abstract][Full Text] [Related]
54. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.
Parney IF; Kunwar S; McDermott M; Berger M; Prados M; Cha S; Croteau D; Puri RK; Chang SM
J Neurosurg; 2005 Feb; 102(2):267-75. PubMed ID: 15739554
[TBL] [Abstract][Full Text] [Related]
55. IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells.
Kozak RW; Lorberboum-Galski H; Jones L; Puri RK; Willingham MC; Malek T; Fitzgerald DJ; Waldmann TA; Pastan I
J Immunol; 1990 Oct; 145(8):2766-71. PubMed ID: 2212661
[TBL] [Abstract][Full Text] [Related]
56. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta.
Nagai T; Tanaka M; Tsuneyoshi Y; Xu B; Michie SA; Hasui K; Hirano H; Arita K; Matsuyama T
Cancer Immunol Immunother; 2009 Oct; 58(10):1577-86. PubMed ID: 19238383
[TBL] [Abstract][Full Text] [Related]
57. Novel anti-brain tumor cytotoxins specific for cancer cells.
Debinski W; Gibo DM; Obiri NI; Kealiher A; Puri RK
Nat Biotechnol; 1998 May; 16(5):449-53. PubMed ID: 9592393
[TBL] [Abstract][Full Text] [Related]
58. Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells.
Kawakami M; Kawakami K; Puri RK
Cancer Immunol Immunother; 2002 Feb; 50(12):691-700. PubMed ID: 11862421
[TBL] [Abstract][Full Text] [Related]
59. Novel way to increase targeting specificity to a human glioblastoma-associated receptor for interleukin 13.
Debinski W; Gibo DM; Puri RK
Int J Cancer; 1998 May; 76(4):547-51. PubMed ID: 9590132
[TBL] [Abstract][Full Text] [Related]
60. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
